Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

Share

.2004 Jun;142(3):495-500.
doi: 10.1038/sj.bjp.0705792. Epub 2004 May 17.

Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist

Affiliations

Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist

Terry Luk et al. Br J Pharmacol.2004 Jun.

Abstract

1 The relationship of agonist efficacy to the rate of G protein-coupled receptor signaling desensitization is controversial. 2 Expressing inwardly rectifying potassium channels (GIRKs) in Xenopus oocytes, we have devised a signaling assay that clearly identifies CB1 cannabinoid receptor agonists with low intrinsic efficacy. 3 In this assay, the synthetic CB1 agonists, AM411, AM782, AM1902, AM2233 and WIN55,212-2 and the endogenous cannabinoid, 2-arachidonoyl ester, were full agonists. 4 The synthetic CB1 agonist AM356 (methanandamide), the endogenous cannabinoids, anandamide and 2-arachidonoyl ether, and the phytocannabinoid, Delta9THC, were partial agonists. 5 The rate of desensitization of CB1 was independent of agonist efficacy. WIN55,212-2, AM782, AM1902, AM2233, and 2-arachidonoyl glycerol ester all desensitized quickly, with desensitization rates varying from 14% min(-1) to 10% min(-1). AM356, AM411, anandamide, and Delta9THC all desensitized considerably slower, at a rate of 5% min(-1). 6 Despite high potency and efficacy, AM411 desensitized as slowly as anandamide and Delta9THC. 7 CB1 agonist efficacy and rate of desensitization are not necessarily related.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Calculation of agonist efficacy and rate of desensitization. (a) Oocytes injected with 0.025 ng oocyte−1 of CB1 and 0.02 ng oocyte−1 of GIRK channel were perfused with high potassium buffer. CB1 agonist was applied after GIRK current stabilized. The amplitude of response to agonist (Iagonist) was compared to the amplitude of response to 1μM WIN55,212-2 (I1μMWIN), giving ‘% Maximal WIN Response' (b) Oocytes were injected with 0.05 ng oocyte−1 CB1 cRNA, 0.02 ng oocyte−1 GIRK channel, 0.625 ng oocyte−1 GRK3, and 4 ng oocyte−1 bovine Arrestin3. After GIRK current stabilized, oocytes were perfused with 1μM WIN55,212-2 for 5 min followed by application of 1μM SR141716. Desensitization was defined as the difference between the current at the beginning and end of the trace, normalized to the initial current. The rate was defined as the percent desensitized per minute.
Figure 2
Figure 2
Decreasing the amount of CB1 cRNA injected reveals partial agonism of anandamide and AM356. (a) Oocytes were injected with 0.02 ng oocyte−1 GIRK channel and either 2.0 or 0.15 ng oocyte−1 CB1 cRNA. WIN55,212-2, anandamide, and AM356 were applied to oocytes in concentrations ranging from 1 nM to 10μM and results are expressed as ‘% Maximal WIN Response.' In oocytes expressing 2.0 ng oocyte−1 CB1 cRNA, all agonists fully activated the current by 1μM. However, in oocytes expressing 0.15 ng oocyte−1 CB1 cRNA, 1μM anandamide and AM356 only activated the current to 25–30% of the WIN55,212-2 response. Thus, 0.15 ng oocyte−1 of CB1 cRNA unmasked the partial agonism of AM356 and anandamide. (b) WIN55,212-2, a full agonist, and AM356 and anandamide, both lower efficacy agonists, elicited the same GIRK current at 1μM in oocytes injected with 2.0 ng oocyte−1 of CB1 cRNA. However, in oocytes injected with 0.15 ng oocyte−1 of CB1 cRNA, 1μM AM356 and anandamide only elicited 25–30% of the WIN-activated currents. The number of oocytes tested for each condition is indicated in parentheses.
Figure 3
Figure 3
Dose–response curves for endogenous, plant-derived and synthetic agonists. (a) Oocytes were perfused with AM1902, AM782, AM2233, AM411, and WIN55,212-2 at the indicated concentrations. Despite widely varying EC50's, all compounds showed full agonism. (b) Oocytes were perfused with anandamide, AM356, 2-AG (ester), 2-AG ether, Δ9-THC, and WIN55,212-2 at the indicated concentrations. 2-AG and WIN55,212-2 were fully efficacious at 10μM, whereas, 2-AG ether, Δ9-THC, anandamide, and AM356 elicited only 40–60% of the Maximal WIN Response at 10μM (N=11–20 per concentration).
Figure 4
Figure 4
Relationship between CB1 affinity and EC50 for GIRK current activation. EC50's (determined from the data in Figure 3) andKi (from same sources as Table 2) are well correlated, except for 2-AG (affinity lower than predicted by EC50) and AM2233 (EC50 lower than predicted by affinity).
Figure 5
Figure 5
Representative traces showing desensitization with selected agonists. Oocytes were injected with 0.05 ng oocyte−1 CB1 cRNA, 0.02 ng oocyte−1 GIRK channel, 0.625 ng oocyte−1 GRK3, and 4 ng oocyte−1 Arrestin3. Oocytes were perfused with high potassium buffer. After GIRK currents stabilized, agonists (WIN55,212-2, AM411, AM356, and 2-AG ether, as labeled) were applied at the indicated concentrations for 5 min, followed by application of 1μM SR141716.
Figure 6
Figure 6
Agonist desensitization rates. (a) Desensitization rates of fully efficacious agonists varied greatly. Desensitization rates were determined as previously described in ‘Methods.' Using a one-way ANOVA nonparametric test, statistical analysis of the desensitization rates of the highly efficacious agonists (all at 1μM) were compared to 1μM WIN55,212-2 (P<0.001 (**),P<0.05 (*)). (b) Less efficacious agonists desensitized more slowly than WIN55,212-2. To evaluate whether or not desensitization rates correlate with agonist efficacy, the desensitization rates of agonists and WIN55,212-2 at equally efficacious concentrations were determined. The desensitization rate of 100 nM WIN55,212-2 was not quite statistically different from 1μM WIN 55,212-2 withP>0.08 (^). 10μM Δ9-THC, 10μM AM356, and 1μM AM411 all desensitized at significantly slower rates compared to 100 nM WIN55,212-2 (P<0.001(**)), however, the desensitization rate of 10μM 2-AG ether was not statistically different from 100 nM WIN55,212-2 (P>0.17).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. ALVAREZ V.A., ARTTAMANGKUL S., DANG V., SALEM A., WHISTLER J.L., VON ZASTROW M., GRANDY D.K., WILLIAMS J.T. mu-Opioid receptors: ligand-dependent activation of potassium conductance, desensitization, and internalization. J. Neurosci. 2002;22:5769–5776. - PMC - PubMed
    1. BREIVOGEL C.S., SELLEY D.E., CHILDERS S.R. Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem. 1998;273:16865–16873. - PubMed
    1. DASCAL N. The use of Xenopus oocytes for the study of ion channels. CRC Crit. Rev. Biochem. 1987;22:317–387. - PubMed
    1. DUTTAROY A., YOBURN B.C. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 1995;82:1226–1236. - PubMed
    1. FAN F., COMPTON D.R., WARD S., MELVIN L., MARTIN B.R. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J. Pharmacol. Exp. Ther. 1994;271:1383–1390. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp